1,3-dioxa-5-thia-s-indacene-6-carboxylic acid | 4791-82-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 1,3-dioxa-5-thia-s-indacene-6-carboxylic acid
• 英文别名: thieno[20,3’:4,5]benzo[1,2-d][1,3]dioxole-6-carboxylic acid；5,6-Methylendioxybenzothiophen-2-carboxylsaeure；5,6-Methylendioxy-benzothiophen-carbonsaeure-(2)；Thieno[2,3-f]-1,3-benzodioxole-6-carboxylic acid；thieno[2,3-f][1,3]benzodioxole-6-carboxylic acid
• CAS: 4791-82-6
• 化学式: C₁₀H₆O₄S
• 分子量: 222.221
• InChiKey: DDYQAKGAKIASSJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  84
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1,3-dioxa-5-thia-s-indacene-6-carboxylic acid 在 氢氧化钾 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  DNA binding ligands targeting drug-resistant Gram-positive bacteria. Part 1: Internal benzimidazole derivatives

  摘要：

  Novel DNA minor-groove binding ligands with a promising antibacterial profile are described. Apart from excellent in vitro potency against multiple Gram-positive bacterial strains such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), and penicillin-intermediate Streptococcus pneumoniae (PISP), a small subset of compounds was active against Gram-negative bacteria such as Escherichia coli (E. coli). (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.042
• 作为产物：
  描述：

  methyl 1,3-dioxa-5-thia-s-indacene-6-carboxylate 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以87%的产率得到1,3-dioxa-5-thia-s-indacene-6-carboxylic acid
  参考文献：
  名称：

  DNA Binding Ligands Targeting Drug-Resistant Bacteria:  Structure, Activity, and Pharmacology

  摘要：

  We describe the lead optimization and structure-activity relationship of DNA minor-groove binding ligands, a novel class of antibacterial molecules. These compounds have been shown to target A/T-rich sites within the bacterial genome and, as a result, inhibit DNA replication and RNA transcription. The optimization was focused on N-terminal aromatic heterocycles and C-terminal amines and resulted in compounds with improved in vivo tolerability and excellent in vitro antibacterial potency (MIC greater than or equal to 0.031 mug/mL) against a broad range of Grainpositive pathogens, including drug-resistant strains such as methicillin-resistant Stapylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), and vancomycin-resistant Enterococcus faecalis (VRE). In a first proof-of-concept study, a selected compound (35) showed in vivo efficacy in a mouse peritonitis model against methicillin-sensitive S. aureus infection with an ED50 value of 30 mg/kg.

  DOI：

  10.1021/jm030097a

文献信息

• 苯并五元不饱和杂环类化合物或其药用盐及其 制备方法、药物组合物及其应用
  申请人：中国医学科学院医药生物技术研究所

  公开号：CN103130705B

  公开（公告）日：2016-04-20

  本发明提供了具有如通式I所示结构的苯并五元不饱和杂环化合物或其药用盐及其制备方法、药物组合物及其应用。实验表明，本发明所述的化合物具有上调骨形成蛋白BMP-2表达活性，抗体内抗骨质疏松作用，并具有改善SAMP6小鼠骨质疏松症状的效果；体外活性测试显示，本发明化合物表现出对骨形态发生蛋白BMP-2表达的明显上调作用。
• [DE] 2-HETEROARYLCARBONSÄUREAMIDE<br/>[EN] 2-HETEROARYLCARBOXYLIC ACID AMIDES<br/>[FR] AMIDES D'ACIDE 2-HETEROARYLCARBOXYLIQUE
  申请人：BAYER AG

  公开号：WO2003055878A1

  公开（公告）日：2003-07-10

  Die Erfindung betrifft neue 2-Heteroarylcarbonsäureamide, Verfahren zu ihrer Herstellung sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prophylaxe von Krankheiten und zur Verbesserung der Wahrnehmung, Konzentrationsleistung, Lernleistung und/oder Gedächtnisleistung.

  该发明涉及新型的2-杂环芳基羧酰胺，其制备方法以及其用于制备用于治疗和/或预防疾病以及改善感知、注意力、学习和/或记忆能力的药物的使用。
• 2-Heteroarylcarboxylic acid amides
  申请人：Hendrix Martin

  公开号：US20050119325A1

  公开（公告）日：2005-06-02

  The invention relates to novel 2-heteroarylcarboxamides, processes for their preparation, and their use for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory.

  本发明涉及新型2-杂环芳基甲酰胺、其制备方法以及用于制备治疗和/或预防疾病以及改善感知、注意力、学习和/或记忆的药物的用途。
• 2-HETEROARYLCARBOXYLIC ACID AMIDES
  申请人：Hendrix Martin

  公开号：US20100222378A1

  公开（公告）日：2010-09-02

  The invention relates to novel 2-heteroarylcarboxamides, processes for their preparation, and their use for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory.

  该发明涉及新型2-杂环芳基甲酰胺、其制备方法及其用于制备治疗和/或预防疾病以及改善感知、注意力、学习和/或记忆的药物。
• Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties
  作者：Si-tu Xue、Lei Zhang、Zhuo-song Xie、Jie Jin、Hui-Fang Guo、Hong Yi、Zong-ying Liu、Zhuo-rong Li

  DOI：10.1016/j.ejmech.2020.112465

  日期：2020.8

  The bone morphogenetic protein (BMP) pathway is a promising new target for the design of therapeutic agents for the treatment of low bone mass. This study optimized the structure of the anti-osteoporosis compound 38 by balancing its lipophilicity and improving its stability. Twenty derivatives which were not reported in the literature were designed and synthesized. The ovariectomized rat model of osteoporosis was selected to evaluate the therapeutic effects. Compound 125 showed better therapeutic efficacy than that of 38. We verified the anti-osteoporosis activity and BMP-2 protein upregulation after treatment with 125 in a zebrafish osteoporosis model. We found that 125 improved the ADME properties, therapeutic efficacy, and pharmacokinetics of the drug. Overall, we evaluated the anti-osteoporosis effects of the compounds of this type, preliminarily determined the target patient population, verified the mechanism of action, clarified the level of toxicity, and provided preliminary ADME data. We believe that these compounds can both correct bone loss that is already occurring in patients and have broad clinical applicability. (C) 2020 Elsevier Masson SAS. All rights reserved.